| Immune-correlates analysis of an HIV-1 vaccine efficacy trial BF Haynes, PB Gilbert, MJ McElrath, S Zolla-Pazner, GD Tomaras, ... New England Journal of Medicine 366 (14), 1275-1286, 2012 | 2110 | 2012 |
| Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG GD Tomaras, G Ferrari, X Shen, SM Alam, HX Liao, J Pollara, ... Proceedings of the National Academy of Sciences 110 (22), 9019-9024, 2013 | 454 | 2013 |
| SARS-CoV-2 variant B. 1.1. 7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines X Shen, H Tang, C McDanal, K Wagh, W Fischer, J Theiler, H Yoon, D Li, ... Cell host & microbe 29 (4), 529-539. e3, 2021 | 421 | 2021 |
| SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination R Pajon, NA Doria-Rose, X Shen, SD Schmidt, S O’Dell, C McDanal, ... New England Journal of Medicine 386 (11), 1088-1091, 2022 | 366 | 2022 |
| Adjuvanting a subunit COVID-19 vaccine to induce protective immunity PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ... Nature 594 (7862), 253-258, 2021 | 288 | 2021 |
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial R Gottardo, RT Bailer, BT Korber, S Gnanakaran, J Phillips, X Shen, ... PloS one 8 (9), e75665, 2013 | 257 | 2013 |
| The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120 N Karasavvas, E Billings, M Rao, C Williams, S Zolla-Pazner, RT Bailer, ... AIDS research and human retroviruses 28 (11), 1444-1457, 2012 | 249 | 2012 |
| Neutralization of SARS-CoV-2 variants B. 1.429 and B. 1.351 X Shen, H Tang, R Pajon, G Smith, GM Glenn, W Shi, B Korber, ... New England Journal of Medicine 384 (24), 2352-2354, 2021 | 245 | 2021 |
| Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals GD Tomaras, JM Binley, ES Gray, ET Crooks, K Osawa, PL Moore, ... Journal of virology 85 (21), 11502-11519, 2011 | 240 | 2011 |
| Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies WB Williams, HX Liao, MA Moody, TB Kepler, SM Alam, F Gao, K Wiehe, ... Science 349 (6249), aab1253, 2015 | 222 | 2015 |
| Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition M Vaccari, SN Gordon, S Fourati, L Schifanella, NPM Liyanage, ... Nature medicine 22 (7), 762-770, 2016 | 214 | 2016 |
| Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques H Li, S Wang, R Kong, W Ding, FH Lee, Z Parker, E Kim, GH Learn, ... Proceedings of the National Academy of Sciences 113 (24), E3413-E3422, 2016 | 207 | 2016 |
| Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion WM Bogers, H Oostermeijer, P Mooij, G Koopman, EJ Verschoor, D Davis, ... The Journal of infectious diseases 211 (6), 947-955, 2015 | 181 | 2015 |
| Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial S Zolla-Pazner, AC deCamp, T Cardozo, N Karasavvas, R Gottardo, ... PloS one 8 (1), e53629, 2013 | 176 | 2013 |
| Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques S Santra, GD Tomaras, R Warrier, NI Nicely, HX Liao, J Pollara, P Liu, ... PLoS pathogens 11 (8), e1005042, 2015 | 161 | 2015 |
| Towards a population-based threshold of protection for COVID-19 vaccines D Goldblatt, A Fiore-Gartland, M Johnson, A Hunt, C Bengt, D Zavadska, ... Vaccine 40 (2), 306-315, 2022 | 141 | 2022 |
| Defining the risk of SARS-CoV-2 variants on immune protection MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ... Nature 605 (7911), 640-652, 2022 | 138 | 2022 |
| Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge T Bradley, J Pollara, S Santra, N Vandergrift, S Pittala, C Bailey-Kellogg, ... Nature communications 8 (1), 15711, 2017 | 138 | 2017 |
| Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies Z Zhu, HR Qin, W Chen, Q Zhao, X Shen, R Schutte, Y Wang, G Ofek, ... Journal of virology 85 (21), 11401-11408, 2011 | 128 | 2011 |
| In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth X Shen, RJ Parks, DC Montefiori, JL Kirchherr, BF Keele, JM Decker, ... Journal of virology 83 (8), 3617-3625, 2009 | 128 | 2009 |
Georgia TomarasProfessor, Depts of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke在 duke.edu 的电子邮件经过验证
